Table 3.

Univariate and multivariate analyses of progression-free survival

Variables	Univariate analysis		Multivariate analysis
	HR (95%CI)	P value	HR (95%CI)	P value
Gender
Male	1
Female	1.90(0.96-5.90)	0.064
Age (years)
≤55	1
>55	1.50(0.73-2.90)	0.280
Tumor differentiation
Poorly differentiated	1
Well or moderately differentiated	0.55(0.27-1.10)	0.090
Chemotherapy regimen
Platinum and fluorouracil (Group 1)	1
Platinum, fluorouracil and taxane (Group 2)	0.83(0.43-1.60)	0.580
NACT response
PR	1
SD	0.97(0.51-1.90)	0.930
Tumor regression grading (Mandard system)
Grade 2 or 3	1
Grade 4	2.20(1.10-4.70)	0.029	2.06(0.94-4.52)	0.070
Downstaging
Yes	1
No	2.40(1.20-4.80)	0.011	1.70(0.81-3.55)	0.159
CD4 (continuous, 10 units)
Pre-NACT	1.00(0.91-1.20)	0.550
Change	0.89(0.72-1.10)	0.290
CD8 (continuous, 10 units)
Pre-NACT	1.10(0.88-1.30)	0.540
Change	0.80(0.66-0.98)	0.030	0.79(0.63-0.99)	0.041
PD-1 (continuous, 10 units)
Pre-NACT	1.00(0.87-1.20)	0.680
Change	0.85(0.71-1.00)	0.069
PD-L1 (continuous, 10 units)
Pre-NACT	1.10(0.91-1.30)	0.310
Change	0.78(0.59-1)	0.075
TIM3 (continuous, 10 units)
Pre-NACT	0.99(0.83-1.20)	0.910
Change	0.90(0.71-1.10)	0.360
FOXP3 (continuous, 10 units)
Pre-NACT	0.97(0.81-1.20)	0.810
Change	0.88 (0.72-1.10)	0.200